Science

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

lifelinecelltech.com

Mar 7, 2025, 03:20

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:

“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!

Phase 2, randomized trial.
105 patients, single-center (European Institute of Oncology, Milan).
SBRT (30 Gy/3 fx) ± 6 months ADT.”

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Authors: Giulia Marvaso, et al.

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Ankara University cancer Emre Yekedüz European Institute of Oncology fight against cancer Giulia Marvaso Global fight against cancer MedOnc OncoDaily Oncology prostate cancer SBRT

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham